Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Brainstorm Cell (NQ: BCLI )

3.435 USD -0.095 (-2.69%)
Streaming Delayed Price Updated: 10:55 AM EDT, Sep 20, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Brainstorm Cell

< Previous 1 2 3 4 5 6 7 8 9 Next >
BrainStorm Announces Second Quarter 2021 Financial Results and Provides a Corporate Update
Continuing to assess regulatory strategy for advancing NurOwn® towards potential approval in ALS 
From PR Newswire
BrainStorm Increases Commercial Manufacturing Capacity; Granted GMP Certification for a Second Production Site in Israel
GMP certification of three state-of-the-art cleanrooms more than doubles the Company's manufacturing capacity for NurOwn® in Israel 
From PR Newswire
BrainStorm to Announce Second Quarter Financial Results and Provide a Corporate Update
From PR Newswire
Brainstorm Announces Expansion of NurOwn® IP Portfolio with Grant and Allowance of Multiple Patents and Applications in Major Markets
Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the grant and/or allowance of a series of patents... 
From PR Newswire
BrainStorm Announces Scientific Presentation of NurOwn® Exosome Preclinical ARDS Data at ISCT 2021 New Orleans VIRTUAL Meeting
Superior clinical and biomarker outcomes demonstrated with NurOwn exosomes compared to MSC exosomes in Preclinical ARDS Model 
From PR Newswire
BrainStorm Announces First Quarter 2021 Financial Results and Provides a Corporate Update
- Positive Phase 2 data demonstrate the potential of NurOwn® as a treatment for progressive MS 
From PR Newswire
BrainStorm to Announce First Quarter Financial Results and Provide a Corporate Update
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that the Company will hold a conference call to update... 
From PR Newswire
Thinking about buying stock in Dolphin Entertainment, Hall of Fame Resort & Entertainment, Aptose Biosciences, Cinedigm, or Brainstorm Cell Therapeutics?
InvestorsObserver issues critical PriceWatch Alerts for DLPN, HOFV, APTO, CIDM, and BCLI. 
From PR Newswire
BrainStorm Announces Positive Topline Data in Phase 2 Study Evaluating NurOwn® as a Treatment for Progressive MS
NurOwn® was shown to be safe and well tolerated 
From PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Brainstorm Cell Therapeutics Inc. - BCLI
Pomerantz LLP is investigating claims on behalf of investors of Brainstorm Cell Therapeutics Inc. ("Brainstorm" or the "Company") (NASDAQ: BCLI). Such investors are advised to contact Robert S.... 
From PR Newswire
Tenax Therapeutics, Inc. Expands Board of Directors
Tenax Therapeutics, Inc. (NASDAQ: TENX) appoints June Almenoff, MD, PhD, Michael Davidson, MD, Delcan Doogan, MD, and Stuart Rich, MD to its Board. 
From Business Wire News Releases
Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Brainstorm Cell Therapeutics Inc. (BCLI) Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Brainstorm Cell Therapeutics Inc. ("Brainstorm" or "the Company") (NASDAQ: BCLI). Investors who purchased... 
From Business Wire News Releases
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Brainstorm Cell Therapeutics Inc. - BCLI
Pomerantz LLP is investigating claims on behalf of investors of Brainstorm Cell Therapeutics Inc. ("Brainstorm" or the "Company") (NASDAQ: BCLI). Such investors are advised to contact Robert S.... 
From PR Newswire
Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Brainstorm Cell Therapeutics Inc. (BCLI) Investigation
Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Brainstorm Cell Therapeutics Inc. ("Brainstorm" or "the Company") (NASDAQ: BCLI).... 
From Business Wire News Releases
BrainStorm to Present at SVB Leerink 10th Global Healthcare Conference
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that members of the management team will participate... 
From PR Newswire
BrainStorm Announces High-Level FDA Feedback on NurOwn® ALS Clinical Development Program
FDA recommended generating additional clinical data to meet FDA's BLA requirements 
From PR Newswire
BrainStorm Announces Feedback from FDA Type-C Meeting on Future NurOwn® Manufacturing Plan
FDA provided guidance on introducing semi-automated manufacturing in the future for commercialization 
From PR Newswire
BrainStorm Announces Full Year 2020 Financial Results and Provides a Corporate Update
- Company met with the FDA to present phase 3 data and is in ongoing discussions with the FDA to identify agreed upon regulatory pathways that may support NurOwn's future approval in ALS 
From PR Newswire
BrainStorm-Cell Therapeutics to Announce Fourth Quarter and Fiscal Year 2020 Financial Results and Provide a Corporate Update
From PR Newswire
BrainStorm Announces the Publication of Preclinical Data Highlighting the Potential of a NurOwn® Derived Exosome-Based Treatment for COVID-19 ARDS
Intratracheal administration of NurOwn® derived exosomes significantly improves lung function and histology in a mouse model of acute respiratory distress syndrome (ARDS) 
From PR Newswire
BrainStorm Issues 2020 Letter to Shareholders
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the following letter from its Chief Executive Officer, Chaim... 
From PR Newswire
BrainStorm Announces Completion of All Dosing in NurOwn® Phase 2 MS Study
Topline clinical trial results expected by the end of the first quarter 2021 
From PR Newswire
BrainStorm Announces NurOwn® Expanded Access Program
NurOwn® will be made available for ALS patients who completed all Phase 3 clinical trial assessments and meet specific eligibility criteria 
From PR Newswire
BrainStorm to present NurOwn® Phase 3 Clinical Trial Results at 31st International Symposium on ALS/MND
- Dr. Merit Cudkowicz and Dr. Ralph Kern presentation will be featured in Oral Presentation in the Clinical Trials Platform Session 
From PR Newswire
BrainStorm Announces Topline Results from NurOwn® Phase 3 ALS Study
Clinical trial did not meet statistical significance in primary efficacy endpoint 
From PR Newswire
Rapid Reshore & Development and BrainStorm Cell Therapeutics Announce Agreement to Advance Construction of BrainStorm's U.S. Manufacturing Facility
RR&D to lead site selection and design 
From PR Newswire
Catalent and BrainStorm Cell Therapeutics Announce Partnership for the Manufacture of Mesenchymal Stem Cell Platform Therapy NurOwn®
From GlobeNewswire News Releases
BrainStorm Announces Scientific Presentation of NurOwn® Exosome Preclinical ARDS Outcomes at the Virtual New York Stem Cell Foundation Conference
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced the presentation of a poster titled, "MSC-NTF (NurOwn®)... 
From PR Newswire
BrainStorm Announces Financial Results for the Third Quarter of 2020 and Provides a Corporate Update
Pivotal Phase 3 ALS trial remains on track for top-line data readout by the end of November 2020 
From PR Newswire
BrainStorm to Present at the 2020 Cell & Gene Meeting on the Mesa
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced Stacy Lindborg, Ph.D., Executive Vice President and... 
From PR Newswire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.